We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Epizyme Inc (EPZM) USD0.0001

Sell:$1.49 Buy:$1.53 Change: $0.04 (2.70%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
Change: $0.04 (2.70%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
Change: $0.04 (2.70%)
Market closed |  Prices as at close on 5 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. It is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The Company is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.

Contact details

400 Technology Sq Ste 4
United States
+1 (617) 2295872

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$250.81 million
Shares in issue:
168.33 million
United States
US dollar

Key personnel

  • Grant Bogle
    President, Chief Executive Officer, Director
  • Jerald Korn
    Chief Operating Officer
  • Jeffery Kutok
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.